Student's killer on parole
Charges after investigation
Hostage was on captor 
Banks must say rebate 
Regulating power prices
Gen X is raking it in
US vetoes UN resolution
$100M Nassar settlement
12 Trump jurors picked
Indigo needs turnaround 
Rates slow green economy
Vicinity hires president,
Warriors ready for Round 2
Kalamalka Bowl cancelled
Rockets live to fight on
Rihanna's parenting ‘hack’
Tarantino scraps film
Munn talks cancer battle
GENEVA - Drugmaker Novartis says it has signed several multibillion-dollar deals with GlaxoSmithKline and Lilly that will affect some 15,000 of its employees.
The Basel, Switzerland-based company said Tuesday it will buy GSK's oncology products business for $14.5 billion, plus up to $1.5 billion more if certain milestones are met.
It will also divest its vaccines business to GSK, excluding its flu business, for $7.1 billion, plus royalties. The two companies are also creating a new consumer health care business through a joint venture.
Separately, Novartis said it will sell off its animal health division to Lilly for about $5.4 billion and plans to sell its flu business.
Novartis CEO Joseph Jimenez told reporters the transactions will raise profits and "affect 15,000 Novartis employees," but didn't specify in which way.
